Lipoprotein Apheresis in Patients With Maximally Tolerated Lipid-Lowering Therapy, Lipoprotein(a)-Hyperlipoproteinemia, and Progressive Cardiovascular Disease: Prospective Observational Multicenter Study
Evidence from prospective epidemiological studies has accumulated to firmly document an association of elevated circulating levels of lipoprotein(a) (Lp(a)) with cardiovascular disease (CVD) including coronary artery disease, cerebrovascular disease, and peripheral artery disease. Lipoprotein apheresis can lower low-density lipoprotein cholesterol and Lp(a) and is the final escalating option in severely hypercholesterolemic patients, including genetic or other forms of hypercholesterolemia resistant to or intolerant of the use of statins or combined lipid-lowering medication. The major effect of lipoprotein apheresis is the prevention of cardiovascular events. The Pro(a) LiFe study showed that commencing chronic lipoprotein apheresis could reduce the incidence rate of cardiovascular events in patients with Lp(a)-hyperlipoproteinemia and progressive CVD that persisted despite the maximal treatment of other concomitant cardiovascular risk factors. Results of this prospective study support the hypothesis that Lp(a) might be a causal factor for progression of CVD in patients with Lp(a)-hyperlipoproteinemia. Efforts must be made to identify these patients to optimize their treatment including multimodality approaches. The assessment of cardiovascular risk, in particular, for patients who are already at high risk owing to established CVD should include measurement of Lp(a). Lp(a) levels are generally not influenced by lifestyle. A widely useable substance for effective pharmacological lowering of Lp(a) is not yet available. Nicotinic acid at high doses has shown a Lp(a)-lowering effect in clinical practice. Limited by side effects, the use of nicotinic acid has not seen wide application. In Europe, nicotinic acid is no longer available. Lipoprotein apheresis can be regarded as a reasonable and available therapeutic option for high-risk patients with Lp(a)-hyperlipoproteinemia and progressive CVD. See p 2567.
National Trends in Heart Failure Hospitalization After Acute Myocardial Infarction for Medicare Beneficiaries: 1998-2010
Heart failure (HF) is a serious complication of acute myocardial infarction (AMI) that has a substantial impact on patient survival and quality of life. With advances in AMI and HF care over the past decade, whether the medical community has successfully decreased the risk of HF after AMI is an important unanswered question. Using a complete sample of Medicare fee-for-service beneficiaries from 1998 through 2010, our study found that the rate of HF hospitalization within 1 year after AMI decreased from 16.1 to 14.2 per 100 personyears during this time period. Considerable differences in the HF hospitalization rate after AMI were observed across race and sex, with black women having nearly twice the HF hospitalization rate compared with white men. One-year mortality after HF hospitalization following AMI remained high at 45.5% in 2010, and in fact has increased slightly since 2007. Overall, the modest decline in HF hospitalization after AMI may represent improvements in completeness of revascularization, emphasis of secondary prevention efforts, or secular shifts towards more outpatient care for AMI patients who subsequently develop HF. However 1-year mortality remains high in this elderly population; the trend towards increasing mortality for HF after AMI in recent years is concerning and warrants additional attention. See p 2577.
Sick Sinus Syndrome in HCN1-Deficient Mice
Sinus node dysfunction (SND) is a major clinically relevant disease that is associated with sudden cardiac death and is responsible for >50% of surgical implantations of permanent pacemakers Volume 128 ◼ Number 24 ◼ December 17, 2013
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per year worldwide. Although the pathologies of acquired SND have been studied in detail, little is known about the molecular and cellular mechanisms that cause congenital SND. This article reports for the first time that mice lacking the pacemaker channel HCN1 display congenital SND characterized by bradycardia, sinus dysrhythmia, prolonged sinoatrial node recovery time, increased sinoatrial conduction time, and recurrent sinus pauses. As a consequence of SND, HCN1-deficient mice display a severely reduced cardiac output. Our study has important clinical impact. Because HCN1 is expressed in the human sinoatrial node, this channel may be added to the list of candidate genes associated with human sinoatrial node dysfunction. Mutations in HCN1 could be well tolerated and thus could be relevant for human disease. HCN1-selective blockers have been considered for the treatment of epileptic disorders, chronic pain, and depression. Given the functional importance of HCN1 for cardiac pacemaking, selective HCN1 blockers should be carefully tested with respect to potential adverse effects on sinoatrial node function. In conclusion, we propose that HCN1 stabilizes the leading pacemaker region within the sinoatrial node and hence is crucial for stable heart rate and regular beat-to-beat variation. Furthermore, we suggest that HCN1-deficient mice may be a valuable genetic disease model for human SND. See p 2585.
Temporal Differences in Out-of-Hospital Cardiac Arrest Incidence and Survival
Out-of-hospital cardiac arrest (OHCA) occurs in >300 000 individuals in the United States each year and remains associated with very high mortality. Successful resuscitation requires implementing a "chain of survival" with both prehospital and hospital-based links, including activation of emergency medical services, early cardiopulmonary resuscitation, defibrillation as appropriate, advanced life support measures, and postresuscitation care in the hospital. The association between the time of cardiac arrest and outcomes remains poorly understood. Understanding temporal differences in OHCA incidence and survival has important implications for developing preventative strategies and optimizing systems for care. We studied >18 000 OHCA events of presumed cardiac origin from the Cardiac Arrest Registry to Enhance Survival, a central repository of OHCA data from >70 emergency medical services agencies and 340 hospitals throughout the United States and found significant variability in the frequency of OHCA by hour of the day, day of the week, and month of the year, with the highest incidence during the daytime, on Saturday, and in December. We also found that survival to hospital discharge was lowest for OHCA that occurred overnight and during the winter, even after adjustment for patient, event, and prehospital care differences. Further exploration of the relative contribution of patient pathophysiology, likelihood of being observed, and prehospital and hospital-based resuscitative factors (including staffing, dispatch procedures, number of vehicles able to respond, quality of cardiopulmonary resuscitation, and use of neuroprotective therapy and cardiac investigations) is required in efforts to understand and mitigate this temporal disparity and improve overall OHCA outcomes. See p 2595.
